The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 33.00
Bid: 31.80
Ask: 32.90
Change: 0.00 (0.00%)
Spread: 1.10 (3.459%)
Open: 32.90
High: 33.00
Low: 31.90
Prev. Close: 33.00
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amendment to Long-Term Incentive Plan

11 Jun 2013 15:52

RNS Number : 8066G
EKF Diagnostics Holdings PLC
11 June 2013
 



 

 

 

11 June 2013

EKF Diagnostics Holdings plc

("EKF" or the "Company" or the "Group")

 

Amendment to EKF's Long-Term Incentive Plan

 

EKF Diagnostics Holdings plc (AIM: EKF), the growing in-vitro diagnostics company, announces that it has amended one of the performance conditions for certain awards already made under the existing EKF Long-Term Incentive Plan ("LTIP") to better incentivise key executives. The Board of Directors recognises the importance of incentivising and rewarding the performance of its key executives, and securing greater alignment of shareholders' and management's interests with transparency over performance targets.

 

The Board, following the recommendation of the Remuneration Committee and after consulting its advisers, has today made the following amendment to the performance conditions attached to the awards made to each of David Evans, Executive Chairman, and Julian Baines, Chief Executive Officer, under the LTIP. The LTIP was adopted on 25 November 2009 and the awards made to Mr Evans and Mr Baines were detailed in an announcement made by the Company on 24 September 2010.

 

The Board believes that this amendment does not materially re-base the performance parameters of the original awards. In summary, the total number of options remains unchanged and the exercise price remains unchanged. The amendment allows for a defined percentage of the options to vest over a five year period, subject to defined performance conditions. The overall dilution effect of the exercise of these options remains unchanged. A summary of the amendment is provided below:

 

·; Options over 8,545,638 ordinary shares, representing 3.13 per cent. of the current issued share capital, divided equally between Mr Evans and Mr Baines, are now subject to the Company's share price reaching certain levels before 31 December 2016. Approximately one fifth of the options (i.e. options over approximately 1,709,128 shares) will vest if the Company's mid-market closing share price reaches the following levels for a period of 20 consecutive days (on which the London Stock Exchange is open for business) before 31 December 2016: 30p, 37.5p, 45p and 52.5p. Approximately one fifth of the options (i.e. options over approximately 1,709,128 shares) will vest if the Company's mid-market closing share price reaches 60p for a period of 30 consecutive days (on which the London Stock Exchange is open for business) ending on 31 December 2016. These options were originally exercisable conditional upon the share price reaching 45p per share within the three years commencing 1 January 2011.

 

All other terms and conditions of these incentivisation arrangements remain unchanged and are in conformity with the Company's existing LTIP.

 

For the avoidance of doubt, the terms relating to a further 8,545,638 ordinary shares, representing 3.13 per cent. of the current issued share capital, divided equally between Mr Evans and Mr Baines which are subject to the achievement of a compound annual EBITDA growth for the three years commencing 1st January 2011 remain unchanged.

Amendment to a Related Party Transaction

As these awards under the LTIP were made to executive directors of the Company, they constituted a related party transaction for the purposes of the AIM Rules (as announced on 24 September 2010). Therefore, any amendments to these awards under the LTIP are considered an amendment to a related party transaction.

The non-executive Directors (none of which are affected by the amendment to the LTIP) consider, having consulted with the Company's Nominated Adviser, Canaccord Genuity, that the amendment to the LTIP is fair and reasonable insofar as its Shareholders are concerned.

Amendments to the option certificate for Richard Evans, Finance Director

In addition, the Board, following the recommendation of the Remuneration Committee, has amended the option certificate for Richard Evans, Finance Director, following his grant of 4,260,000 options (representing, if exercised, 1.56 per cent. of the Company's current issued share capital) on 15 June 2011 (prior to his appointment as Finance Director) so that all of the Option Shares are subject to a three year EBITDA test (previously half of the options were subject to a performance condition based on a three year EBITDA test with the remaining half incorrectly subject to a performance condition based on the Company's share price).

 

All other terms and conditions of these incentivisation arrangements remain unchanged and are in conformity with the Company's existing LTIP.

 

 

Summary of Amendment to EKF's Long-Term Incentive Plan

 

The original awards made to Mr Evans and Mr Baines under the LTIP together with the amendment to their performance conditions, which are exactly the same for both Mr Evans and Mr Baines, are detailed below:

 

Original LTIP Awards (24 Sep 2010)

Amended LTIP Performance Conditions

Options over 8,545,638 ordinary shares, representing, if exercised, a further 6.00 per cent. of the then issued share capital, again divided equally between Mr Evans and Mr Baines.

 

These options were exercisable at 15 pence per share, conditional upon the share price reaching 45 pence per share, a trebling of the 15 pence per share price at which the July 2010 placing was undertaken, within the three years commencing 1 January 2011.

 

Options over a further 8,545,638 (unchanged) ordinary shares, representing, if exercised, a further 3.13 per cent. of the current issued share capital, again divided equally between Mr Evans and Mr Baines.

 

The exercise price of these options remains unchanged at 15 pence.

 

The performance condition for the first 1,709,128 Award Shares is that the Company's mid-market closing share price attains 30 pence.

 

The performance condition for the next 1,709,128 Award Shares is that the Company's mid-market closing share price attains 37.5 pence.

 

The performance condition for the next 1,709,128 Award Shares is that the Company's mid-market closing share price attains 45 pence.

 

The performance condition for the next 1,709,128 Award Shares is that the Company's mid-market closing share price attains 52.5 pence.

 

The performance condition for the remaining 1,709,126 Award Shares is that the Company's mid-market closing share price attains 60 pence.

 

For the share price performance criteria to be met, the Company's share must reach and maintain the aforementioned levels for a period of 20 consecutive days (on which the London Stock Exchange is open for business) at any time during the period commencing on 1 January 2012 and ending on 31 December 2016, save that for the Award Shares subject to the Company's mid-market closing share price attaining 60 pence, this share price must be reached and maintained for a period of 30 consecutive days (on which the London Stock Exchange is open for business) ending on 31 December 2016.

 

 

 

 

Enquiries:

 

EKF Diagnostics Holdings plc

Tel: 029 2071 0570

 

David Evans, Executive Chairman

Mob: 07740 084 452

 

Julian Baines, CEO

Mob: 07788 420 859

 

 

 

Canaccord Genuity Limited

Lucy Tilley / Henry Fitzgerald-O'Connor / Julian Feneley

Tel: 020 7523 8000

 

Walbrook PR Limited

Tel: 020 7933 8780

 

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

 

Paul Cornelius

Mob: 07866 384 707 or paul.cornelius@walbrookpr.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKMGMVDMGGFZM
Date   Source Headline
25th Aug 20152:58 pmRNSForm 8.3 - EKF Diagnostics Holdings plc
25th Aug 20152:36 pmBUSForm 8.3 - EKF Diagnostics Holdings Plc
25th Aug 20152:15 pmRNSForm 8.3 - EKF Diagnostics Holdings Plc
25th Aug 20151:10 pmRNSHolding(s) in Company
25th Aug 201511:54 amPRNForm 8.3 - EKF Diagnostics Holdings Plc
25th Aug 201511:30 amBUSForm 8.3 - EKF Diagnostics Holdings Plc
25th Aug 201510:52 amRNSHolding(s) in Company
24th Aug 201511:19 amRNSForm 8.3 - EKF Diagnostics Holdings Plc
24th Aug 20157:01 amRNSAnnouncement under rule 2.4 of the Takeover Code
24th Aug 20157:00 amRNSFurther non-binding proposal
18th Aug 201512:00 pmRNSConclusion of Strategic Review
18th Aug 201511:55 amRNSTrading update
10th Aug 20159:25 amRNSHolding(s) in Company
19th May 20152:26 pmRNSResult of AGM
13th May 20157:00 amRNSLaunch of PrecisionPath Colon
1st May 20153:15 pmRNSPosting of Annual Report & Notice of AGM
24th Apr 20154:44 pmRNSHolding(s) in Company
21st Apr 20151:17 pmRNSData for PointMan Technology presented at AACR
8th Apr 201511:41 amRNSHolding(s) in Company
8th Apr 201511:36 amRNSHolding(s) in Company
2nd Apr 20157:00 amRNSShareholder update
26th Mar 20153:47 pmRNSHolding(s) in Company
25th Mar 20153:05 pmRNSHolding(s) in Company
19th Mar 20159:40 amRNSHolding(s) in Company
18th Mar 20153:41 pmRNSHolding(s) in Company
16th Mar 20157:00 amRNSFinal Results
2nd Mar 20157:00 amRNSCollaboration to improve colon cancer treatment
23rd Feb 20157:00 amRNSNotice of results & investor results presentation
2nd Feb 20157:00 amRNSChange of Adviser
28th Jan 20157:00 amRNSTrading update
23rd Jan 20157:00 amRNSCorporate Collaboration
23rd Jan 20157:00 amRNSPointMan collaboration with ANGLE plc
5th Jan 20157:00 amRNSPayment of DiaSpect's deferred consideration
17th Dec 20147:00 amRNSTrading update & potential Board appointment
11th Nov 20144:46 pmRNSHolding(s) in Company
1st Oct 201411:36 amRNSDirector/PDMR Shareholding
23rd Sep 20147:00 amRNSUS collaboration to develop blood tests for cancer
15th Sep 20147:00 amRNSHalf Yearly Report
15th Aug 20147:00 amRNSDirectorate Change
13th Aug 20147:00 amRNSNotice of results and investor briefing
23rd Jul 20147:00 amRNSTrading update
8th Jul 20147:00 amRNSContract Win and Regulatory Approval
13th Jun 201412:53 pmRNSHolding(s) in Company
9th Jun 20145:59 pmRNSGrant of Share Options
6th Jun 20142:46 pmRNSHolding(s) in Company
2nd Jun 20144:15 pmRNSHolding(s) in Company
2nd Jun 20147:00 amRNSMajor step towards detecting cancer in blood
2nd Jun 20147:00 amRNSDirectorate Change
27th May 20143:59 pmRNSHolding(s) in Company
23rd May 201411:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.